Gekko for me it’s about valuation.
I think the company is very undervalued given where it’s at in its development.
Agree with all your points but the ship has been turned onto the right course.
New trials started to expand CE mark including percutaneous
New hospitals and docs using it.
Resection rate holding up
Potential in other tumours
Its in a growing therapeutic area of interest
In a sale process I would have expected 100-150 million because that’s what it would cost to get to this point.
I’d dearly love aFDA nod or a German ok to convince the market but I fear the market isn’t listening
Gekko for me it’s about valuation. I think the company is very...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
0.015(1.48%) |
Mkt cap ! $14.65M | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.05 | 95.0¢ | $109.7K | 112.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23906 | $1.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 2292 | 2 |
View Market Depth
| Last trade - 15.57pm 19/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |